New AHA/ACC Acute PE Guidelines: A–E Categories and PERT Class 1 Activation

01 Apr 20264 min read0 views

GIST

The first-ever AHA/ACC clinical practice guideline on acute pulmonary embolism drops a new A-to-E severity classification, promotes PERT teams to Class 1, and finally says it: DOACs over warfarin, LMWH over UFH. Here’s what emergency physicians need to know… Creager MA et al.

2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines . Circulation.

2026 Mar 24;153(12):e977-e1051. The 2011 AHA scientific statement on massive and submassive PE was widely used but it was not a clinical practice guideline.

The 2019 ESC guidelines from Europe became the de facto standard for many clinicians. This 2026 document is the first dedicated AHA/ACC clinical practice guideline for acute PE in adults.

It is a big deal. A completely new severity classification.

The old language of massive, submassive, and low-risk…is gone. In its place: AHA/ACC Acute PE Clinical Categories A through E , with subcategories.

Clinical Editorial

Summary

A New Framework for Acute Pulmonary Embolism: Sizing Up the 2026 AHA/ACC Guideline

Overview of the guideline evolution

The 2026 document represents the first dedicated AHA/ACC clinical practice guideline for acute PE in adults.
It replaces the prior terminology of massive, submassive, and low-risk with a newly defined A through E severity framework, augmented by subcategories and a respiratory modifier (R) applied when hypoxia, tachypnea, or escalating oxygen needs are present.
This update articulates explicit management pathways tied to each category and emphasizes risk stratification, biomarker assessment, and multidisciplinary response planning via PE response teams (PERT).

Study design and authoritative positioning

The guideline consolidates recommendations from a broad consortium of professional societies and positions PERT activation as a Class 1, Level B-NR intervention for patients (Categories C–E) who meet criteria for heightened risk or instability.
The transition from older nomenclature to the A–E framework aims to standardize triage decisions, escalation, and disposition across care settings, including potential outpatient management for lower-risk categories.

Population and risk stratification logic

The schema delineates Categories A and B as suitable candidates for home-based management in appropriate cases, with outpatient treatment supported by decision tools such as Hestia, PESI, or sPESI.
Categories C through E warrant inpatient care with a structured assessment that includes at least one cardiac biomarker and imaging-based risk stratification.
Lactate measurement is newly codified as a Class 1 recommendation for Categories C–E, reflecting its role in identifying systemic perfusion concerns.

Biomarkers, imaging, and risk assessment

Cardiac biomarkers (troponin or BNP) should be measured in patients within Categories C–E to support risk stratification.
Right ventricular (RV) imaging is recommended for risk stratification, with echocardiography favored over CT when feasible; this imaging informs subsequent management pathways.
The guideline also reiterates the importance of incorporating lactate status into the risk assessment framework for higher-risk categories.

Therapeutic implications and anticoagulation strategy

In adults eligible for oral anticoagulation, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists (VKAs), provided there are no contraindications.
Reasons cited for favoring DOACs include lower recurrent VTE risk with low major bleeding risk relative to warfarin, predictable dosing, avoidance of routine monitoring, and fewer food/drug interactions.
Low-molecular-weight heparin (LMWH) is favored over unfractionated heparin (UFH) due to reduced recurrent VTE risk, predictable dosing, lack of routine monitoring, and a lower risk of heparin-induced thrombocytopenia.
Special populations and caveats:
Obesity (BMI > 30): DOACs are considered reasonable over warfarin, including in severe obesity, per available analyses of apixaban and rivaroxaban in this subgroup.
Antiphospholipid syndrome (APS): Warfarin remains preferred, with DOACs associated with higher arterial thrombotic events in thrombotic APS; a DOAC may be considered only in a single-antibody, low-risk APS without prior arterial thrombosis.
Pregnancy: LMWH or UFH only; DOACs or warfarin are classified as potentially harmful.
Kidney disease (stages 2–3): DOACs favored over warfarin; in stage 4–5 or dialysis, apixaban may be considered but data are uncertain.
Liver disease: DOACs reasonable for Child-Pugh A and B; avoid DOACs in Child-Pugh C.
A nuanced point notes that if catheter-directed interventions are pursued for select patients, choice between CDL (catheter-directed lysis) and MT (mechanical thrombectomy) should be individualized, as the PEERLESS trial found no significant difference in 30-day mortality or major bleeding between these approaches in 550 randomized patients.

Operational and practical implications

step-down vs.

ward-level care decisions.

The guideline emphasizes a structured approach to categorization and subsequent management, with a clear emphasis on risk-adapted therapy.
For Categories C–E, a PERT activation is recommended, reinforcing the need for rapid, coordinated multidisciplinary input in complex cases.
The proposed framework integrates biomarker data, lactate levels, and RV function as central to risk stratification and decision-making, potentially affecting ICU vs.
The outpatient pathways for Categories A and B rely on validated triage tools, and the strength of the evidence supporting these pathways is highlighted as randomized trial data underpinning the Class 2a recommendation.

Limitations and uncertainties

The content notes that the framework, while evidence-informed, hinges on evolving data for several subgroups (e.g., high-obesity patients, certain APS contexts, and advanced liver or kidney disease scenarios), indicating areas where evidence remains imperfect or uncertain.
Specific numerical outcomes, absolute effect sizes, and trial-by-trial details are not provided within the summary content, nor are numeric thresholds for all category delineations, which are not stated here.
Some recommendations are positioned with Class 3 harm for DOACs in pregnancy and certain liver conditions, highlighting explicit contraindications in those populations.